Parcourir par sujet "canagliflozin"
Voici les éléments 1-5 de 5
-
Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
(2022)For almost two decades, the management of patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and blood pressure control as well as on the adequate blockade of ... -
Mechanisms for cardiorenal protection of sglt-2 inhibitors
(2021)Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially ... -
Novel Therapeutic Strategies for Cardiorenal Protection in Patients with Type 2 Diabetes and Chronic Kidney Disease
(2022)Type 2 diabetes mellitus (T2DM) is the leading cause of end-stage kidney disease (ESKD) worldwide [1]. The development of chronic kidney disease (CKD) in patients with T2DM sub-stantially increases their risk for cardiovascular ... -
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
(2022)[No abstract available] -
Supracardiac atherosclerosis in embolic stroke of undetermined source: The underestimated source
(2021)The term ‘embolic stroke of undetermined source’ (ESUS) is used to describe patients with a non-lacunar ischaemic stroke without any identified embolic source from the heart or the arteries supplying the ischaemic territory, ...